06 Sep 2016 | Fujirebio Europe launches Lumipulse® G HMW Adiponectin for aid in diagnosis of insulin resistance in obesity and of metabolic syndrome

Gent, Belgium – September 6, 2016 – Fujirebio Europe today announced the release of Lumipulse G HMW Adiponectin, a biomarker useful in the diagnosis of insulin resistance in obesity and of metabolic syndrome, available on the fully automated LUMIPULSE G series of instruments.

“Manual and semi-manual ELISA testing for adiponectin has existed in clinical laboratories for years but our new HMW Adiponectin assay for the LUMIPULSE G series opens up to testing for this biomarker in routine clinical laboratories.” said Christiaan De Wilde, CEO of Fujirebio Europe. “Our automated instruments offer high reliability and very low turnaround time and we will therefore also be helping laboratories save time and cost.“

 
About HMW Adiponectin
Interest for HMW Adiponectin is growing rapidly today in established specialized centers for routine diagnosis and plays a crucial and causal role in obesity linked insulin resistance and metabolic syndrome1. Furthermore, the decreased levels of serum adiponectin represent an independent risk factor for nonalcoholic fatty liver disease (NAFLD) and liver dysfunctions in humans2.

 
About Fujirebio
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.

Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.

For more information about Fujirebio please visit www.fujirebio-europe.com.

 
References:

  1. T Yamauchi and T Kadowaki Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. International Journal of Obesity (2008) 32, S13–S18
  2. Yu Wang et al. Protective roles of adiponectin in obesityrelated fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metab. 2009;53/2
CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.